Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis

Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis

Publication date: Aug 12, 2019

The aim of this research is to understand how lipids such as cholesterol affect the disease process in people with MS.

Concepts Keywords
Alemtuzumab Conduct protocol
Autoimmune Autoimmune disease
Avonex Immune system
Azathioprine Interferon beta-1a
Biomedical Autoimmunity
Blood Multiple sclerosis
Breast Feeding Hematology
Cholesterol RTT
CIS Immunology
Copaxone Immunosuppressants
Corticosteroids Clinical medicine
Cyclophosphamide Medicine
Demographic Medical specialties
Fat Multiple Sclerosis
Fingolimod MS
Force Conditions concomitant diseases
Gilenya Conduct protocol
Immune Complex Insurance system
Immune Function
Immunosuppressive Drugs
Infection
Informed Consent
Insurance
Interferon Beta
Lipid
Lipids
London
London General
Membrane
Molecule
Multiple Sclerosis
Myelin
Natalizumab
Nerve
Pharmacist
Plasma Membrane
Primary Endpoint
Protocol
Rebif
Statins
Tysabri

Semantics

Type Source Name
disease MESH Sclerosis
disease DOID cancer
disease MESH cancer
disease MESH infection
drug DRUGBANK Etoperidone
drug DRUGBANK Cyclophosphamide
drug DRUGBANK Azathioprine
drug DRUGBANK Alemtuzumab
drug DRUGBANK Natalizumab
drug DRUGBANK Teriflunomide
drug DRUGBANK Fingolimod
drug DRUGBANK Dimethyl fumarate
drug DRUGBANK Acetate ion
drug DRUGBANK Glatiramer
drug DRUGBANK Interferon beta-1a
gene UNIPROT IFNB1
gene UNIPROT CISH
disease MESH diagnosis
drug DRUGBANK Cholesterol
gene UNIPROT DNMT1
gene UNIPROT CD69
disease DOID Multiple Sclerosis
disease MESH Multiple Sclerosis
disease DOID Autoimmune Disease
disease MESH Autoimmune Disease

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *